Precision Medicine in CNS Drug Development

By Daniel Klamer, PhD, Anavex Life Sciences Corp.

Precision medicine, which has been pioneered by the field of oncology, aims to target the right treatments to the right patients at the right time. Recent advances in genomics and imaging, as well as the discovery of other biomarkers, have enabled precision medicine to become a more viable treatment option. The next frontier in this type of medicine may be in the treatment of central nervous system disorders.

This white paper, based on the webinar, evaluates the following:

  • What lessons can we learn from the use of precision medicine in oncology?
  • How has a recent clinical precision medicine application shown potential in the treatment of Alzheimer’s?
  • What questions should you ask before you add a new biomarker to your clinical trial?
  • What are the pros and cons of using biomarkers as surrogate endpoints?


the white paper